Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Sector Update: Financial Stocks Lower in Afternoon Trading

Sector Update: Financial Stocks Lower in Afternoon Trading

MT newswireMT newswire2026/09/23 17:55
01:55 PM EDT, 09/23/2026 (MT Newswires) -- Financial stocks declined in Wednesday afternoon trading, with the NYSE Financial Index dropping 0.6% and the State Street Financial Select Sector SPDR ETF (XLF) easing 0.1%. The Philadelphia Housing Index and the State Street Real Estate Select Sector SPDR ETF (XLRE) each declined about 1.1%. Bitcoin (BTC-USD) fell 3.2% to $83,854, and the yield for 10-year US Treasuries jumped 15 basis points to 5.12%. In economic news, the September flash reading of manufacturing conditions from S&P Global rose to a 52-month high of 57 from 53.9 in August, and compared with 53.7 in a Bloomberg survey. US mortgage applications fell 1.5% for the week ending Sept. 18, compared with a decline of 4.1% in the week prior, as the 30-year fixed-rate mortgage rate increased to 7.12% from 6.97% over the same period. In corporate news, Blue Owl Capital (OWL) could see its junior loan to Loparex wiped out as Monarch Alternative Capital and General Atlantic lead a roughly $1 billion restructuring that will see them own a majority of the business, Bloomberg reported. Blue Owl shares were falling 2.7%. A Morgan Stanley (MS) employee accidentally leaked an internal list of more than 100 investment-banking deals the firm is monitoring and pitching in Asia, Bloomberg reported. Morgan Stanley shares were shedding 0.7%. Brookfield (BN) is nearing a deal to buy financial crime and compliance specialist Actimize from NICE (NICE) for $2 billion, Sky News reported. Brookfield shares were down 1.5%.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released

October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)

路透社•2026/10/06 07:26